Microvesicles: the functional mediators in sorafenib resistance

Abstract

Overcoming drug resistance in cancer therapies remains challenging, and the tumor microenvironment plays an important part in it. Microvesicles (MVs) are functional natural carriers of cellular information, participate in intercellular communication, and dynamically regulate the tumor microenvironment. They contribute to drug resistance by transferring functional molecules between cells. Conversely, due to their specific cell or tissue targeting ability, MVs are considered as carriers for therapeutic molecules to reverse drug resistance. Thus, in this mini-review, we aim to highlight the crucial role of MVs in cell-to-cell communication and therefore their diverse impact mainly on liver cancer progression and treatment. In addition, we summarize the possible mechanisms for sorafenib resistance (one of the main hurdles in hepatocellular carcinoma treatments) and recent advances in using MVs to reverse sorafenib resistance in liver cancer therapies. Identifying the functional role of MVs in cancer therapy might provide a new aspect for developing precise novel therapeutics in the future.

Keywords

Microvesicles (MVs) / sorafenib resistance / tumor microenvironment / cancer therapy

References

[1] Villanueva A.Hepatocellular carcinoma.N Engl J Med2019;380:1450-62

[2] Wilhelm S,Lynch M.Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.Nat Rev Drug Discov2006;5:835-44

[3] Chang YS,Trail PA.Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.Cancer Chemother Pharmacol2007;59:561-74

[4] Wilhelm SM,Tang L.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.Cancer Res2004;64:7099-109

[5] Chen KF,Tai WT.Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.J Pharmacol Exp Ther2011;337:155-61

[6] Li Y,Han Z,Qiao L.IL-6/STAT3 Signaling contributes to sorafenib resistance in hepatocellular carcinoma through targeting cancer stem cells.Onco Targets Ther2020;13:9721-30 PMCID:PMC7533247

[7] Yang F,Gong ZB.MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment.Technol Cancer Res Treat2014;13:77-86

[8] Zhu YJ,Wang HY.New knowledge of the mechanisms of sorafenib resistance in liver cancer.Acta Pharmacol Sin2017;38:614-22 PMCID:PMC5457690

[9] Chen J,Zhao J.Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma.Cancer Lett2015;367:1-11

[10] Lemoinne S,Housset C.The emerging roles of microvesicles in liver diseases.Nat Rev Gastroenterol Hepatol2014;11:350-61

[11] Camussi G.Deregibus M, Tetta C. Tumor-derived microvesicles and the cancer microenvironment.Curr Mol Med2012;13:58-67

[12] Clancy JW,D’Souza-Schorey C.Tumor-derived microvesicles in the tumor microenvironment: how vesicle heterogeneity can shape the future of a rapidly expanding field.Bioessays2015;37:1309-16

[13] Balaj L,Dai L.Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences.Nat Commun2011;2:180 PMCID:PMC3040683

[14] D’Souza-Schorey C.Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers.Genes Dev2012;26:1287-99 PMCID:PMC3387656

[15] Jaffar Ali D,Xu H.Microvesicles mediate sorafenib resistance in liver cancer cells through attenuating p53 and enhancing FOXM1 expression.Life Sci2021;271:119149

[16] Villanueva A,Chiang DY,Llovet JM.Genomics and signaling pathways in hepatocellular carcinoma.Semin Liver Dis2007;27:55-76

[17] Calvisi DF,Gorden A.Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.Gastroenterology2006;130:1117-28

[18] Liu L,Chen C.Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.Cancer Res2006;66:11851-8

[19] Llovet JM,Mazzaferro V.SHARP Investigators Study GroupSorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.

[20] Abou-Alfa GK,Ricci S.Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.J Clin Oncol2006;24:4293-300

[21] Awada A,Gil T.Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.Br J Cancer2005;92:1855-61 PMCID:PMC2361774

[22] Ratain MJ,Stadler WM.Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.J Clin Oncol2006;24:2505-12

[23] Ziogas IA.Ziogas IA, Tsoulfas G. Evolving role of Sorafenib in the management of hepatocellular carcinoma.World J Clin Oncol2017;8:203-13 PMCID:PMC5465010

[24] Tang DP,Wang XJ.Sorafenib plus capecitabine of patients with advanced hepatocellular carcinoma.China Pharm2008;19:848-9

[25] Tang W,Zhang W.The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects.Signal Transduct Target Ther2020;5:87 PMCID:PMC7292831

[26] Xia S,Liang Y,Cai X.The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma.EBioMedicine2020;51:102610 PMCID:PMC7000339

[27] Ito Y,Sakon M.Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma.Br J Cancer2001;84:1377-83 PMCID:PMC2363640

[28] Zhang Z,Shen H,Wang Y.Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study.BMC Med2009;7:41 PMCID:PMC2738687

[29] Blivet-Van Eggelpoël MJ,Fartoux L.Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.J Hepatol2012;57:108-15

[30] Zhai B,Jiang X.Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma.Mol Cancer Ther2014;13:1589-98

[31] Morgensztern D.PI3K/Akt/mTOR pathway as a target for cancer therapy.Anticancer Drugs2005;16:797-803

[32] Wu B,Zhang Y.Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles.Expert Opin Drug Deliv2020;17:573-87

[33] Zhang H,Liu J.Inhibition of the PI3K/Akt signaling pathway reverses sorafenib-derived chemo-resistance in hepatocellular carcinoma.Oncol Lett2018;15:9377-84 PMCID:PMC6004698

[34] Chen KF,Hsu CY.Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity.Eur J Med Chem2012;55:220-7

[35] Miranda A,Zhang AW.Cancer stemness, intratumoral heterogeneity, and immune response across cancers.Proc Natl Acad Sci USA2019;116:9020-9 PMCID:PMC6500180

[36] Lo RC,Chan KK.Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/β-catenin pathway.Cell Death Differ2018;25:1426-41 PMCID:PMC6113239

[37] Ma S,Zheng BJ,Guan XY.CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.Oncogene2008;27:1749-58

[38] Xin HW,Hari DM.Label-retaining liver cancer cells are relatively resistant to sorafenib.Gut2013;62:1777-86 PMCID:PMC6993136

[39] Sukowati CH,Crocè LS.Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma.World J Hepatol2010;2:114-26 PMCID:PMC2998960

[40] Fung SW,Yip CW.The ATP-binding cassette transporter ABCF1 is a hepatic oncofetal protein that promotes chemoresistance, EMT and cancer stemness in hepatocellular carcinoma.Cancer Lett2019;457:98-109

[41] Yang Y,Wei MN.Targeting ABCB1-mediated tumor multidrug resistance by CRISPR/Cas9-based genome editing.Am J Transl Res2016;8:3986-94 PMCID:PMC5040697

[42] Cheng CC,Liao CC.The roles of angiogenesis and cancer stem cells in sorafenib drug resistance in hepatocellular carcinoma.Onco Targets Ther2019;12:8217-27 PMCID:PMC6783114

[43] Nio K,Kaneko S.The evolving concept of liver cancer stem cells.Mol Cancer2017;16:4 PMCID:PMC5282887

[44] Wang N,Li MY.Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies.Ther Adv Med Oncol2018;10:1758835918816287 PMCID:PMC6304707

[45] Takebe N,Harris PJ.Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update.Nat Rev Clin Oncol2015;12:445-64 PMCID:PMC4520755

[46] Tang Y,Mavila N.Inhibition of CREB binding protein-beta-catenin signaling down regulates CD133 expression and activates PP2A-PTEN signaling in tumor initiating liver cancer cells.Cell Commun Signal2018;16:9 PMCID:PMC5848530

[47] Tang J,Wen D.MiR-612 suppresses the stemness of liver cancer via Wnt/β-catenin signaling.Biochem Biophys Res Commun2014;447:210-5

[48] Tlemsani C,Arrondeau J.Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.Expert Opin Drug Metab Toxicol2015;11:785-94

[49] Zimmerman EI,Li L.Ontogeny and sorafenib metabolism.Clin Cancer Res2012;18:5788-95 PMCID:PMC3490489

[50] Edginton AN,Vasilyeva A,Panetta JC.Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice.Cancer Chemother Pharmacol2016;77:1039-52 PMCID:PMC4846505

[51] Gerth K,Mahon M,Verma N.Circulating extracellular vesicles containing xenobiotic metabolizing CYP enzymes and their potential roles in extrahepatic cells via cell-cell interactions.Int J Mol Sci2019;20:6178 PMCID:PMC6940889

[52] Almazroo OA,Venkataramanan R.Drug metabolism in the liver.Clin Liver Dis2017;21:1-20

[53] Alonso-peña M,Sanchon-sanchez P,Espinosa-escudero R.Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma.Cancer Drug Resist2019;2:680-709

[54] Liu JE,Tang L.The independent contribution of miRNAs to the missing heritability in CYP3A4/5 functionality and the metabolism of atorvastatin.Sci Rep2016;6:26544 PMCID:PMC4876377

[55] Karbownik A,Grabowski T.Pharmacokinetic drug interaction study of Sorafenib and morphine in rats.Pharmaceutics2021;13:2172 PMCID:PMC8707786

[56] Miners JO,Rowland A.Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.Biochem Pharmacol2017;129:85-95

[57] Cui CP,Kai AK.SENP1 promotes hypoxia-induced cancer stemness by HIF-1α deSUMOylation and SENP1/HIF-1α positive feedback loop.Gut2017;66:2149-59 PMCID:PMC5749365

[58] Won C,Yi EH.Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma.Hepatology2015;62:1160-73 PMCID:PMC5049669

[59] Straussman R,Shee K.Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.Nature2012;487:500-4 PMCID:PMC3711467

[60] Muralidharan-Chari V,Sedgwick A.Microvesicles: mediators of extracellular communication during cancer progression.J Cell Sci2010;123:1603-11 PMCID:PMC2864708

[61] Konoshenko MY,Vlassov AV.Isolation of Extracellular Vesicles: General Methodologies and Latest Trends.Biomed Res Int2018;2018:8545347 PMCID:PMC5831698

[62] Bian X,Wu T.Microvesicles and chemokines in tumor microenvironment: mediators of intercellular communications in tumor progression.Mol Cancer2019;18:50 PMCID:PMC6441155

[63] Hugel B,Kunzelmann C.Membrane microparticles: two sides of the coin.Physiology (Bethesda)2005;20:22-7

[64] Sedgwick AE.The biology of extracellular microvesicles.Traffic2018;19:319-27 PMCID:PMC6922305

[65] Cocucci E,Meldolesi J.Shedding microvesicles: artefacts no more.Trends Cell Biol2009;19:43-51

[66] Schiera G,Alberti C,Savettieri G.Neurons produce FGF2 and VEGF and secrete them at least in part by shedding extracellular vesicles.J Cell Mol Med2007;11:1384-94 PMCID:PMC4401300

[67] Pizzirani C,Chiozzi P.Stimulation of P2 receptors causes release of IL-1beta-loaded microvesicles from human dendritic cells.Blood2007;109:3856-64

[68] Sidhu SS,Tauscher AN,Basbaum C.The microvesicle as a vehicle for EMMPRIN in tumor-stromal interactions.Oncogene2004;23:956-63

[69] Kornek M,Libermann TA,Schuppan D.Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells.Hepatology2011;53:230-42 PMCID:PMC3505073

[70] Baj-krzyworzeka M,Pratico D.Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells.Exp Hematol2002;30:450-9

[71] van Dommelen SM,Lakhal S.Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery.J Control Release2012;161:635-44

[72] Raposo G.Extracellular vesicles: exosomes, microvesicles, and friends.J Cell Biol2013;200:373-83 PMCID:PMC3575529

[73] Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles.Nat Rev Mol Cell Biol2018;19:213-28

[74] Hoshino A,Shen TL.Tumour exosome integrins determine organotropic metastasis.Nature2015;527:329-35 PMCID:PMC4788391

[75] Ratajczak J,Hayek F,Ratajczak MZ.Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication.Leukemia2006;20:1487-95

[76] Wu S,To KKW.Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer.Mol Cancer2021;20:17 PMCID:PMC7812728

[77] Dionisi M,Battisti F.Tumor-derived microvesicles enhance cross-processing ability of clinical grade dendritic cells.Front Immunol2018;9:2481 PMCID:PMC6230586

[78] Qu Z,Wu J,Jiang C.Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.J Exp Clin Cancer Res2016;35:159 PMCID:PMC5045585

[79] Patton MC,Khan MA,Singh AP.Hypoxia alters the release and size distribution of extracellular vesicles in pancreatic cancer cells to support their adaptive survival.J Cell Biochem2020;121:828-39 PMCID:PMC6878126

[80] Wang X,Chen L.Chemotherapeutic drugs stimulate the release and recycling of extracellular vesicles to assist cancer cells in developing an urgent chemoresistance.Mol Cancer2019;18:182 PMCID:PMC6907227

[81] Yao H,Lin MC.Positive feedback loop between cancer stem cells and angiogenesis in hepatocellular carcinoma.Cancer Lett2016;379:213-9

[82] Lau EY,Cheng BY.Cancer-associated fibroblasts regulate tumor-initiating cell plasticity in hepatocellular carcinoma through c-Met/FRA1/HEY1 signaling.Cell Rep2016;15:1175-89

[83] Li Y,Wang J.CRISPR/Cas systems towards next-generation biosensing.Trends Biotechnol2019;37:730-43

[84] Sun L,Wang L.Resolvin D1 prevents epithelial-mesenchymal transition and reduces the stemness features of hepatocellular carcinoma by inhibiting paracrine of cancer-associated fibroblast-derived COMP.J Exp Clin Cancer Res2019;38:170 PMCID:PMC6472102

[85] Zhang W,Xu XL.Annexin A2 promotes the migration and invasion of human hepatocellular carcinoma cells in vitro by regulating the shedding of CD147-harboring microvesicles from tumor cells.PLoS One2013;8:e67268 PMCID:PMC3741296

[86] Whatcott CJ,Barrett MT,Von Hoff DD.Inhibition of ROCK1 kinase modulates both tumor cells and stromal fibroblasts in pancreatic cancer.PLoS One2017;12:e0183871 PMCID:PMC5571985

[87] Gao Y,Qi Y.Golgi phosphoprotein 3 promotes angiogenesis and sorafenib resistance in hepatocellular carcinoma via upregulating exosomal miR-494-3p.Cancer Cell Int2022;22:35 PMCID:PMC8785582

[88] Takahashi K,Kogure T,Patel T.Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer.FEBS Open Bio2014;4:458-67 PMCID:PMC4050189

[89] Takahashi K,Wood J,Patel T.Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy.Mol Cancer Res2014;12:1377-87 PMCID:PMC4201956

[90] Lou G,Xia C.MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway.J Exp Clin Cancer Res2020;39:4 PMCID:PMC6941283

[91] Lou G,Yang F.Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma.J Hematol Oncol2015;8:122 PMCID:PMC4627430

[92] Semaan L,Lu Y.MicroRNA-214 enriched exosomes from human cerebral endothelial cells (hCEC) sensitize hepatocellular carcinoma to anti-cancer drugs.Oncotarget2021;12:185-98 PMCID:PMC7869574

[93] Li H,Shi Y.Exosomes derived from siRNA against GRP78 modified bone-marrow-derived mesenchymal stem cells suppress Sorafenib resistance in hepatocellular carcinoma.J Nanobiotechnology2018;16:103 PMCID:PMC6300915

[94] Croce CM.Causes and consequences of microRNA dysregulation in cancer.Nat Rev Genet2009;10:704-14 PMCID:PMC3467096

[95] Rabinowits G,Day JM,Kloecker GH.Exosomal microRNA: a diagnostic marker for lung cancer.Clin Lung Cancer2009;10:42-6

[96] Skog J,van Rijn S.Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers.Nat Cell Biol2008;10:1470-6 PMCID:PMC3423894

[97] Ohshima K,Fujiwara A.Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line.PLoS One2010;5:e13247 PMCID:PMC2951912

[98] Dai HY,Lai WC,Li LY.Targeted expression of BikDD combined with metronomic doxorubicin induces synergistic antitumor effect through Bax activation in hepatocellular carcinoma.Oncotarget2015;6:23807-19 PMCID:PMC4695153

[99] Xu S,Shan Q.Self-activated cascade-responsive Sorafenib and USP22 shRNA co-delivery system for synergetic hepatocellular carcinoma therapy.Adv Sci (Weinh)2021;8:2003042 PMCID:PMC7927615

[100] Kao CY.Engineering human megakaryocytic microparticles for targeted delivery of nucleic acids to hematopoietic stem and progenitor cells.Sci Adv2018;4:eaau6762 PMCID:PMC6221511

[101] Fonsato V,Tritta S.Human liver stem cell-derived extracellular vesicles enhance cancer stem cell sensitivity to tyrosine kinase inhibitors through Akt/mTOR/PTEN combined modulation.Oncotarget2018;9:36151-65 PMCID:PMC6281417

[102] Wang G,Wang H.Exosomal MiR-744 Inhibits proliferation and Sorafenib chemoresistance in hepatocellular carcinoma by targeting PAX2.Med Sci Monit2019;25:7209-17 PMCID:PMC6777417

[103] Cooper JM,Nordin JZ.Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice.Mov Disord2014;29:1476-85 PMCID:PMC4204174

[104] Kooijmans SA,Roffler SR,Vader P.Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting.J Extracell Vesicles2016;5:31053 PMCID:PMC4793259

[105] Yoshioka Y.Extracellular vesicles as novel nanocarriers for therapeutic delivery.Nucleic Acid Nanotheranostics2019;391-407

[106] He C,Xu H.Epithelial cell -derived microvesicles: A safe delivery platform of CRISPR/Cas9 conferring synergistic anti-tumor effect with sorafenib.Exp Cell Res2020;392:112040

[107] Wang X,Zhang W.Current status of gene therapy for hepatocellular carcinoma, with a focus on gene delivery approaches.Curr Gene Ther2015;15:120-41

[108] Zhang BC,Zou JJ.Co-delivery of Sorafenib and CRISPR/Cas9 based on targeted core-shell hollow mesoporous organosilica nanoparticles for synergistic HCC therapy.ACS Appl Mater Interfaces2020;12:57362-72

[109] Burnouf T,Agrahari V.Extracellular vesicles as nanomedicine: hopes and hurdles in clinical translation.Int J Nanomedicine2019;14:8847-59 PMCID:PMC6859699

[110] Kailashiya J,Dash D.Engineered human platelet-derived microparticles as natural vectors for targeted drug delivery.Oncotarget2019;10:5835-46 PMCID:PMC6791386

[111] Kanada M,Hardy JW.Microvesicle-mediated delivery of minicircle dna results in effective gene-directed enzyme prodrug cancer therapy.Mol Cancer Ther2019;18:2331-42 PMCID:PMC6891168